


The addition of rituximab to fludarabine and cyclophosphamide chemotherapy significantly improves outcomes in patients with mantle cell lymphoma

370 patients with mantle cell lymphoma were randomized
median follow up of 6 years

fludarabine and
cyclophosphamide



fludarabine and
cyclophosphamide
+

rituximab



Progression Free Survival

14.9 months

($p < 0.001$)

29.8 months

Overall Survival

37.0 months

($p = 0.005$)

44.5 months

Complete response rate

39.9 %

($p = 0.014$)

52.7 %